Pfizer Inc.
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after Pfizer showcased c...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehe...
Latest News
2 days ago · fool.com
Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?Pfizer shares are up amid bullish sentiment about the pharmaceutical company's turnaround efforts. The upcoming loss of patent exclusivity for several blockbuster drugs could prevent a full recovery into 2029.
2 days ago · 247wallst.com
$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in DividendsDividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
2 days ago · seekingalpha.com
Pfizer: Reality Check Ahead Of EarningsPfizer is downgraded from 'Buy' to 'Hold' as analyst sentiment turns increasingly bearish and growth prospects dim. Consensus expects declining revenue and EPS through 2029, with skepticism about management's optimistic growth projections and pipeline potential. Cost-cutting efforts and pipeline updates, including anti-obesity drugs from Metsera, are critical but unlikely to offset looming patent cliffs.
3 days ago · 247wallst.com
Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow.
4 days ago · zacks.com
Exploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPSGet a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
4 days ago · zacks.com
Pfizer (PFE) Stock Sinks As Market Gains: Here's WhyPfizer (PFE) closed at $29.45 in the latest trading session, marking a -1.17% move from the prior day.
4 days ago · zacks.com
Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.
5 days ago · benzinga.com
Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma PatientsPfizer Inc. (NYSE:PFE) on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as a monotherapy.
5 days ago · zacks.com
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 days ago · businesswire.com
Pfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple MyelomaNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment with anti-CD38 therapy (daratumumab or isatuximab) and lenalidomide. At the pre-specified interim analysis for efficacy, the study met its primary endpoint of progression-free survival (PFS) as assessed by blinded ind.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PFE